Mike Zaman's  Instablog

Mike Zaman
Send Message
  • GlobalSCAPE (GSB), Sinovac (SVA), Q3 Strong Financial Performance 0 comments
    Nov 13, 2013 10:03 AM | about stocks: GSB, SVA

    http://static.cdn-seekingalpha.com/uploads/2013/11/13/saupload_gsb1.jpg GlobalSCAPE, Inc. (NYSE MKT:GSB)

    After closing bell on Tuesday's trading session, GSB reported strong earnings growth on its financial results, driven by increased revenue combined with lower operating expenses.

    For the third quarter 2013, GSB posted revenue of $6.3 million, a 3% increase year over year, and net income of $2.3 million or $0.12 per share, compared to a net loss of $2.7 million, or ($0.15) per share, in the same period the prior year.

    http://static.cdn-seekingalpha.com/uploads/2013/11/13/saupload_gsb_chart.png

    GSB ensures the reliability of mission-critical operations by securing sensitive data and intellectual property. GSB's suite of solutions features EFT Server, the industry-leading enterprise file transfer solution that delivers military-grade security and a customizable platform for achieving best in class control and visibility of data in motion or at rest, across multiple locations.

    More about GlobalSCAPE, Inc. GlobalSCAPE, Inc. (NYSE MKT:GSB) at www.globalscape.com

    **

    http://static.cdn-seekingalpha.com/uploads/2013/11/13/saupload_sva.jpg Sinovac Biotech Ltd. (Nasdaq:SVA)

    SVA reported on its unaudited financial results another strong quarter with revenue growth, which resulted in another profitable quarter on a sequential quarterly basis.

    For the third quarter 2013, SVA posted total sales of $22.1 million, a 54.5% increase year over year, gross profit of $15.9 million, a 111.7% increase compared to the same period the prior year, and net income attributable to common stockholders of $2.3 million, or $0.04 per basic and diluted share, compared to net loss of $3.0 million, or ($0.05) per basic and diluted share in the third quarter 2012.

    http://static.cdn-seekingalpha.com/uploads/2013/11/13/saupload_sva_chart2.png

    SVA is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and mumps, as well as animal rabies vaccine for canines.

    More about Sinovac Biotech Ltd. (Nasdaq:SVA) at www.sinovac.com

    **

    Read Full Disclaimer at www.pennyomega.com/disclaimer

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: GSB, SVA
Back To Mike Zaman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.